Stroke prevention in the high-risk atrial fibrillation patient: Medical management

被引：3

作者：

Broukhim M. ^{[1
]}

Halperin J.L. ^{[1
]}

机构：

[1] Cardiovascular Institute, Mount Sinai Medical Center, Box 1030, New York, NY 10029

来源：

Current Cardiology Reports | 2011年 / 13卷 / 1期

关键词：

Anticoagulation; Atrial fibrillation; Dabigatran; Dronedarone; Factor Xa inhibitors; Mechanical heart valve; Rheumatic heart disease; Stroke; Warfarin;

D O I：

10.1007/s11886-010-0148-z

中图分类号：

学科分类号：

摘要：

Medical management of patients with atrial fibrillation (AF) at high risk for stroke is limited by problems of imperfect tools for assessment of thromboembolism and bleeding risks. Improved instruments, such as the CHA 2DS2VASc and HAS-BLED risk stratification scores, have been incorporated into European practice guidelines. Until recently, the most effective therapy for stroke prevention has been anticoagulation with a vitamin K antagonist, but new oral anticoagulants in development, antiarrhythmic drugs that reduce adverse cardiovascular events in patients with AF, and interventional techniques for occlusion of the left atrial appendage represent promising options for stroke prevention. These new strategies will need focused evaluation in the most challenging AF patients-those with a high risk of bleeding, prior thromboembolism, or thrombosis-prone surfaces such as mechanical heart valve prostheses or drug-eluting coronary stents, for whom the limitations of currently available treatment options and a paucity of data are particularly acute. © 2010 Springer Science+Business Media, LLC.

引用

页码：9 / 17

页数：8

共 59 条

[1]

Hart R.G., Pearce L.A., Miller V.T., Anderson D.C., Rothrock J.F., Albers G.W., Nasco E., Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: Frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies, Cerebrovascular Diseases, 10, 1, pp. 39-43, (2000)

[2]

Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Le Heuzey J.-Y., Kay G.N., Lowe J.E., Olsson S.B., Prystowsky E.N., Tamargo J.L., Wann S., Smith Jr. S.C., Jacobs A.K., Adams C.D., Anderson J.L., Antman E.M., Halperin J.L., Hunt S.A., Nishimura R., Ornato J.P., Page R.L., Riegel B., Priori S.G., Blanc J.-J., Budaj A., Camm A.J., Dean V., Deckers J.W., Despres C., Dickstein K., Lekakis J., McGregor K., Metra M., Morais J., Osterspey A., Tamargo J.L.,

[3]

Yamamoto K., Ikeda U., Seino Y., Et al., Coagulation activity is increased in the left atrium of patients with mitral stenosis, J Am Coll Cardiol, 25, pp. 107-112, (1995)

[4]

Wolf P.A., Dawber T.R., Thomas Jr. H.E., Et al., Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study, Neurology, 28, pp. 973-977, (1978)

[5]

Wood P., Diseases of the Heart and Circulation, (1956)

[6]

Ellis L.B., Harken D.E., Arterial embolization in relation to mitral valvuloplasty, Am Heart J, 62, pp. 611-620, (1961)

[7]

Salem D.N., O'Gara P.T., Madias C., Pauker S.G., Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition), Chest, 133, 6 SUPPL. 6, (2008)

[8]

Heras M., Chese J.H., Fuster V., Et al., High risk of thromboemboli early after bioprosthetic cardiac valve replacement, J Am Coll Cardiol, 25, pp. 1111-1119, (1995)

[9]

Baudet E.M., Puel V., McBride J.T., Et al., Long-term results of valve replacement with the St. Jude Medical prosthesis, J Thorac Cardiovasc Surg, 109, pp. 858-870, (1995)

[10]

Horstkotte D., Schulte H., Bircks W., Et al., Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10-year follow-up of patients with St. Jude Medical prostheses, J Heart Valve Dis, 2, pp. 291-301, (1993)

← 1 2 3 4 5 6 →